HONG KONG, April 1, 2026 /PRNewswire/ — On 31 March, Fosun International held its 2025 annual results presentation in Shanghai. Guo Guangchang, Chairman of Fosun International; Wang Qunbin, Co-Chairman of Fosun International; Chen Qiyu, Co-CEO of Fosun International; Xu Xiaoliang, Co-CEO of Fosun International; Gong Ping, CFO of Fosun International, as well as a number of institutional investors and analysts attended the event.
On the evening of 30 March, Fosun International announced its 2025 annual results. During the Reporting Period, the Group’s total revenue reached RMB173.43 billion, and adjusted industrial operation profit was RMB4 billion. Fosun International’s adjusted net asset value (NAV) was RMB133.5 billion, with a NAV per share reaching HKD18.1. Its four core subsidiaries generated RMB128.2 billion in revenue, accounting for 74% of the Group’s total revenue. Among them, Fosun Pharma achieved a net profit attributable to shareholders of the parent of RMB3.371 billion, representing a year-on-year increase of 21.69%. Fosun Insurance Portugal achieved a net profit attributable to owners of the parent of EUR201 million, up 15.8% year-on-year.
Compared to prior years, Fosun’s results have largely remained stable. However, Fosun made non-cash impairment provisions and value revaluations on certain real estate projects with impairment indicators, as well as goodwill and intangible assets of certain non-core business segments. This resulted in a book loss of RMB23.4 billion in 2025, of which real estate-related impairment accounted for approximately 55%, while impairment of non-core assets accounted for approximately 45%. These provisions do not affect the Company’s overall operations and cash flow.
“Repairing the roof on a sunny day”
Guo Guangchang, Chairman of Fosun International, emphasized that this impairment is akin to “repairing the roof on a sunny day”, and from a long-term perspective, this impairment marks Fosun’s entry into a new stage of development. “We will divest assets with low profitability and value below target, and focus our resources on core, high‑growth areas, steering the Company toward a leaner, healthier, and more sustainable future.”
He explained that the operating results of Fosun’s various business segments indicate that Fosun’s core businesses remain solid. The pharmaceutical business has continued to make breakthroughs in its global expansion, with multiple products launched overseas and several …